TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17277036

Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin daily
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: 100 mg vildagliptin daily
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 15489367

Group type: EXPERIMENTAL
Intervention: Low fluoride mouthrinse/toothpaste treatment regime
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-active control combination
Number of subjects: 26
Study: 11574431

Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections or continuous subcutaneous infusion with frequent blood-glucose testing)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Conventional therapy (1-2 injections of insulin per day)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Intensive therapy and Conventional therapy
Number of subjects: 1246
Study: 9213289

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 0
Study: 9316669

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2.5 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30997730

Group type: EXPERIMENTAL
Intervention: High polyphenol extra virgin olive oil (EVOO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low polyphenol olive oil
Number of subjects: 50
Study: 29190252

Group type: EXPERIMENTAL
Intervention: Intracapsular distilled water application using vitrectomy approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 28035016

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (160 mg, range 110-200 mg in the 5 min before exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol maintenance infusion (0.2 mg·kg total body mass-1·min-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esmolol and saline infusion during epinephrine infusion
Number of subjects: 0
Study: 26165688

Group type: EXPERIMENTAL
Intervention: Vinorelbine or docetaxel (group A, n = 44)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ifosfamide-vinorelbine-cisplatin (group B, n = 18)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cisplatin chemoradiotherapy (group C, n = 26)
Number of subjects: 88
Study: 23475823

Group type: EXPERIMENTAL
Intervention: 50 ml of water
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 19
Study: 21221002

Group type: EXPERIMENTAL
Intervention: Subcutaneous continuous glucose monitoring
Number of subjects: 174
Study: 18641196

Group type: EXPERIMENTAL
Intervention: Weekly folic acid supplementation (5000 or 2800 microg)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Daily folic acid supplementation (400 or 200 microg)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group (daily and weekly iron, zinc, and vitamin B‐12 provided)
Number of subjects: 459
Study: 16730617

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1045
Study: 14594761

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 24
Study: 10716467

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 9178918

Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Breathing a hypoxic gas mixture
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Breathing a hypoxic gas mixture combined with intermittent breath holding
Number of subjects: 65
Study: 1586061

Group type: EXPERIMENTAL
Intervention: PPD-T (M. bovis)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PPD-B (M. intracellulare)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PPD-T
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PPD-B
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Dual testing (PPD-T and PPD-B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PPD-B (bioequivalent to PPD-S)
Number of subjects: 192
Study: 3985802

Group type: EXPERIMENTAL
Intervention: Controlled open drainage (gauze in plastic intestinal bag/surgical glove packing of abscesses; wound closure only to the degree needed to prevent evisceration)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Closed drainage (soft rubber or sump drains; complete fascial closure)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Controlled open drainage
Number of subjects: 31
Study: 30860943

Group type: EXPERIMENTAL
Intervention: PreProCare intervention (n = 372)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Usual care (n = 371)
Number of subjects: 743
Study: 30338680

Group type: EXPERIMENTAL
Intervention: Robuvit 300 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 34
Study: 27001568

Group type: EXPERIMENTAL
Intervention: Farletuzumab 1.25 mg/kg
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Farletuzumab 2.5 mg/kg
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Farletuzumab (above median exposure)
Number of subjects: 1100
Study: 24418242

Group type: EXPERIMENTAL
Intervention: DHA-rich oil supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: OA-rich oil supplementation
Number of subjects: 0
Study: 22607851

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 700

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 700
Study: 21486536

Group type: COMPARATOR
Intervention: Dutasteride (2mg/g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Progesterone (40 mg)
Number of subjects: 20
Study: 17885255

Group type: EXPERIMENTAL
Intervention: 12 hours of classroom instruction on stroke recognition and response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 15829836

Group type: EXPERIMENTAL
Intervention: Media campaign consisting of television and newspaper advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-wide campaigns consisting of table tents, brochures, flyers, and posters
Number of subjects: 0
Study: 12099160

Group type: EXPERIMENTAL
Intervention: Policosanol (5 mg/day, increased to 10 mg/day if total cholesterol > 6.1 mmol/L after 6 months)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 10460554

Group type: EXPERIMENTAL
Intervention: Vital capacity inhalational induction technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tidal breathing inhalational induction technique
Number of subjects: 60
Study: 8546283

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 22
Study: 2221412

Group type: EXPERIMENTAL
Intervention: 3-min breathing of 100% O2
Number of subjects: 24

Group type: COMPARATOR
Intervention: four-maximal-breaths of 100% O2
Number of subjects: 24
Study: 833799

Group type: EXPERIMENTAL
Intervention: Spring-loaded clips
Number of subjects: 300

Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 300
Study: 31055875

Group type: EXPERIMENTAL
Intervention: Screening-detected prostate cancer (S-PCa)
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Clinically detected prostate cancer (C-PCa)
Number of subjects: 1918
Study: 28099300

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Plate fixation and Nonoperative treatment
Number of subjects: 160
Study: 26101115

Group type: EXPERIMENTAL
Intervention: NZ$5 monetary incentive
Number of subjects: 400
Study: 22431208

Group type: EXPERIMENTAL
Intervention: PtCr-everolimus eluting stent (EES)
Number of subjects: 42

Group type: COMPARATOR
Intervention: CoCr-everolimus eluting stent (EES)
Number of subjects: 42
Study: 20584709

Group type: EXPERIMENTAL
Intervention: KERARINGS insertion followed by CXL 6 months later
Number of subjects: 10

Group type: COMPARATOR
Intervention: KERARINGS insertion and CXL performed on the same day
Number of subjects: 10
Study: 19901217

Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 439

Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 439
Study: 17914548

Group type: EXPERIMENTAL
Intervention: Subjects with cardiovascular risk factors
Number of subjects: 1007
Study: 12750100

Group type: EXPERIMENTAL
Intervention: argon green laser treatment (multiple 100‐micro m spots at least 750 micro m from the center of the fovea)
Number of subjects: 120

Group type: COMPARATOR
Intervention: observation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: argon green laser treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: argon green laser treatment (higher-intensity laser burns)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: choroidal neovascularization in each treatment group
Number of subjects: 120
Study: 11097147

Group type: EXPERIMENTAL
Intervention: DIC‐effervesc (50 mg diclofenac Na)
Number of subjects: 24

Group type: COMPARATOR
Intervention: DIC‐enteric (50 mg diclofenac Na)
Number of subjects: 24
Study: 9133184

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine (group N25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg edrophonium (group E25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine (group N5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg edrophonium (group E5)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (group SP)
Number of subjects: 48
Study: 8442918

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg every 4 weeks)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160/800 mg 3 days a week)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Dapsone plus pyrimethamine (100 and 25 mg weekly)
Number of subjects: 331
Study: 3529480

Group type: EXPERIMENTAL
Intervention: How to Stop Smoking booklet
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Control (normal way without booklet)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: How to Stop Smoking booklet (at one clinic with no age imbalance)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Control (at one clinic with no age imbalance)
Number of subjects: 1206
Study: 31315861

Group type: EXPERIMENTAL
Intervention: rtfMRI-NFB training to increase activation of the ventral striatum
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: rtfMRI-NFB training to increase activation of the anterior cingulate
Number of subjects: 68
Study: 29604557

Group type: EXPERIMENTAL
Intervention: Acutrak 2 headless compression screws
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two parallel unicortical cancellous screws
Number of subjects: 18
Study: 26920603

Group type: EXPERIMENTAL
Intervention: PCI plus OMT
Number of subjects: 338

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 338
Study: 24993763

Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (ACT) intervention, 8 sessions over 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (offered ACT after 3-month follow-up)
Number of subjects: 0
Study: 20880720

Group type: EXPERIMENTAL
Intervention: EMG‐BF treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40
Study: 19171004

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrates (APCs) with a small quantity of autologous bone graft
Number of subjects: 18

Group type: COMPARATOR
Intervention: Iliac crest bone alone
Number of subjects: 18
Study: 17242080

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1, 1.25, or 1.5 MAC, age‐adjusted
Number of subjects: 54
Study: 15625507

Group type: EXPERIMENTAL
Intervention: Mass media community-wide physical activity intervention (paid advertisements, public relations, community participatory planning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 0
Study: 12096292

Group type: EXPERIMENTAL
Intervention: Conventional care plus a nursing intervention (18-week, 10-contact nursing intervention utilizing problem-solving approaches)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 113
Study: 10440593

Group type: EXPERIMENTAL
Intervention: PPA 12.5 mg tid
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: PPA 25 mg tid
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg/day
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: PPA 75 mg/day with benzocaine gum 96 mg/day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Benzocaine gum 96 mg/day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 7595979

Group type: EXPERIMENTAL
Intervention: Combined pendulum swing and weight-training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Weight-training only
Number of subjects: 9
Study: 2368895

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study: 580509

Group type: EXPERIMENTAL
Intervention: Phenformin and ethyloestrenol
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 314
Study: 31533792

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 959
Study: 27910725

Group type: EXPERIMENTAL
Intervention: ActiPatch medical device
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Medication use
Number of subjects: 1394
Study: 25942434

Group type: EXPERIMENTAL
Intervention: Contact Lens Sensor (CLS) - Triggerfish, Sensimed, Switzerland
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pneumatonometer (control)
Number of subjects: 33
Study: 23567407

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21055479

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 257

Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 257
Study: 20301902

Group type: EXPERIMENTAL
Intervention: Smoking group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tobacco abstinent group
Number of subjects: 40
Study: 17275141

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietary counseling, liquid and multivitamin supplementation)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 108
Study: 15504857

Group type: EXPERIMENTAL
Intervention: Caspofungin alone (50 mg IV once daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caspofungin with nelfinavir (1,250 mg orally twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caspofungin with rifampin (600 mg orally once daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg orally once daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caspofungin (70 mg daily)
Number of subjects: 10
Study: 11746323

Group type: EXPERIMENTAL
Intervention: Restricted Maximum Likelihood (REML) for continuous outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimating Equations (EE) for continuous outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricted Pseudo-Likelihood (REPL) for binary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimating Equations (EE) for binary outcomes
Number of subjects: 0
Study: 9013456

Group type: EXPERIMENTAL
Intervention: Preemptive therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Deferred therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia associated with a CMV syndrome)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preemptive therapy (Ganciclovir use)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Deferred therapy (Ganciclovir use)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preemptive therapy (CMV-associated charges)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Deferred therapy (CMV-associated charges)
Number of subjects: 36
Study: 7843527

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: DRE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic testing
Number of subjects: 0
Study: 6374539

Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intravenous normal saline
Number of subjects: 124

Group type: COMPARATOR
Intervention: Uterine irrigation with cefoxitin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Uterine irrigation with normal saline
Number of subjects: 124
Study: 30501475

Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 29735587

Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 13054

Group type: COMPARATOR
Intervention: Low-dose pitavastatin (1 mg/d)
Number of subjects: 13054
Study: 26747128

Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT) for 3 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: usual care for 3 weeks (control for mCIMT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: electromyography‐triggered neuromuscular stimulation (EMG‐NMS) for 3 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: usual care for 3 weeks (control for EMG‐NMS)
Number of subjects: 159
Study: 24488091

Group type: EXPERIMENTAL
Intervention: Conventional trabeculectomy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sutureless trabeculectomy
Number of subjects: 52
Study: 22978572

Group type: EXPERIMENTAL
Intervention: Incomplete data collection
Number of subjects: 234

Group type: COMPARATOR
Intervention: Complete data collection
Number of subjects: 234
Study: 19666912

Group type: EXPERIMENTAL
Intervention: Early immunosuppressive therapy (cyclophosphamide for 12 months, and steroids)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Late immunosuppressive therapy (initiated when renal function deteriorated)
Number of subjects: 26
Study: 17522939

Group type: EXPERIMENTAL
Intervention: Visual working memory span scores for visual data link (RoboMemo exercise)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Visual working memory span scores in rotating data link (RoboMemo exercise)
Number of subjects: 28
Study: 16479390

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (normally functioning kidneys)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group 2 (split GFR between 20 and 30 ml/min)
Number of subjects: 35
Study: 15364875

Group type: EXPERIMENTAL
Intervention: TP10 (1, 3, 5, 10 mg/kg)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: TP10
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 10810824

Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy plus lateral internal sphincterotomy (LIS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Haemorrhoidectomy alone
Number of subjects: 42
Study: 8841220

Group type: EXPERIMENTAL
Intervention: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of saline plus epinephrine 1:200,000
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of bupivacaine 0.5% with epinephrine 1:200,000
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsule with mesosalpinx infiltration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of preoperative ketoprofen and mesosalpinx block
Number of subjects: 60
Study: 1737967

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo with niacin
Number of subjects: 31
Study: 6741677

Group type: EXPERIMENTAL
Intervention: 10-week behavioral weight control program
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Program adherence post-treatment
Number of subjects: 36
Study: 30922101

Group type: EXPERIMENTAL
Intervention: Single ketamine infusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (six infusions administered thrice weekly over 2 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Weekly maintenance infusions (four additional infusions administered once weekly)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Midazolam (active placebo control)
Number of subjects: 41
Study: 28854569

Group type: EXPERIMENTAL
Intervention: Three-call intervention (n = 236)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: One-call intervention (n = 233)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Control condition (no additional treatment, n = 235)
Number of subjects: 704
Study: 26386556

Group type: EXPERIMENTAL
Intervention: Motivational group interviewing-based safety education
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional educational sessions
Number of subjects: 70
Study: 24843653

Group type: EXPERIMENTAL
Intervention: cilnidipine (10 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: azelnidipine (16 mg/day)
Number of subjects: 19
Study: 21823344

Group type: EXPERIMENTAL
Intervention: TMX + CoQ10
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TMX
Number of subjects: 183

Group type: COMPARATOR
Intervention: CoQ10
Number of subjects: 183